Lathrop Investment Management Corp Has $17.12 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Lathrop Investment Management Corp trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 32,255 shares of the medical research company’s stock after selling 381 shares during the quarter. Thermo Fisher Scientific accounts for about 3.5% of Lathrop Investment Management Corp’s holdings, making the stock its 8th biggest holding. Lathrop Investment Management Corp’s holdings in Thermo Fisher Scientific were worth $17,121,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in TMO. Raleigh Capital Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after acquiring an additional 27 shares during the last quarter. Cedar Mountain Advisors LLC raised its holdings in Thermo Fisher Scientific by 107.0% during the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after buying an additional 46 shares during the last quarter. Operose Advisors LLC raised its holdings in Thermo Fisher Scientific by 250.0% during the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock valued at $53,000 after buying an additional 75 shares during the last quarter. Financial Connections Group Inc. bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at $53,000. Finally, Valley National Advisers Inc. raised its holdings in Thermo Fisher Scientific by 40.5% during the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock valued at $56,000 after buying an additional 32 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on TMO shares. Deutsche Bank Aktiengesellschaft upped their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday. Evercore ISI upped their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Barclays upped their price objective on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a report on Thursday. Raymond James upped their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Finally, Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $606.76.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock valued at $28,513,384 in the last 90 days. Insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded up $1.87 during trading on Friday, hitting $573.60. The company’s stock had a trading volume of 1,438,184 shares, compared to its average volume of 1,317,052. The company has a 50-day moving average of $573.60 and a 200-day moving average of $529.90. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.39. The firm has a market cap of $218.95 billion, a price-to-earnings ratio of 36.79, a P/E/G ratio of 2.41 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.54 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.